"... In PAGE 6: ... Therefore, the within and across age correlations were calculated for all MZ and all DZ twins. Inspection of the difference between MZ and DZ twin within age correlations (on the diagonal in Table4 ) suggests that variance in OA and AP is explained by additive genetic, genetic dominance, and unique environmental effects. MZ cross-corre- lations are also larger than DZ cross-correlations (see off-diagonals in Table 4).... In PAGE 6: ... Inspection of the difference between MZ and DZ twin within age correlations (on the diagonal in Table 4) suggests that variance in OA and AP is explained by additive genetic, genetic dominance, and unique environmental effects. MZ cross-corre- lations are also larger than DZ cross-correlations (see off-diagonals in Table4 ). Inspection of the vari- ances reveals that at age 3, DZ variances exceed MZ variances both in girls and boys.... ..."

"... In PAGE 3: ... As we increase this correlation, the obtained results become more similar. Table1 shows the obt ained results using the penalty algorithm Ap[1] . Using the penalty algorithms Ap[2] and Ap[3] the transposition - based GA had similar behavior.... ..."

"... In PAGE 16: ...Routine use of nutritional supplements solely to pre- vent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of Evidence: C) Table3 describes cardiovascular medications useful for treatment of various stages of HF. Many conditions or behaviors that are associated with an increased risk of structural heart disease can be identified before patients show any evidence of structural abnormali- ties.... In PAGE 19: ... (Levels of Evidence: A, B, and C as appropriate) 21.Beta-blockers and ACEIs should be used in all patients with a recent or remote history of MI regard- less of EF or presence of HF (see Table3 ). (Level of Evidence: A) 3.... In PAGE 21: ... (Level of Evidence: CA) 32. Angiotensin converting enzyme inhibitors are recom- mended for all patients with current or prior symp- toms of HF and reduced LVEF, unless contraindicat- ed (see Table3 and text). (Level of Evidence: A) 43.... In PAGE 21: ... (Level of Evidence: A) 5. Angiotensin II receptor blockers approved for the treatment of HF (see Table3 ) are recommended in patients with current or prior symptoms of HF and reduced LVEF who are ACEI-intolerant (see text for information regarding patients with angioedema). (Level of Evidence: A) 65.... ..."

"... In PAGE 33: ... Table10 summarizes the marginal posterior distributions of parameters of interest. Each distribution conveys the posterior probability that a parameter of interest takes on various values.... In PAGE 33: ... Similarly, the 95% interval in the last column can be viewed as a Bayesian analogue of 95% confidence intervals in the frequentist framework, though of course interpretations differ. In Table10 , we see that the average treatment effect on a logit scale is 0.871 with a 95% interval of (0.... In PAGE 34: ... In connection with this, note that there is a substantial negative correlation between u0j and u1j (Corr(u0j, u1j)=-0.583, Table10 ). This correlation indicates that the effect of EAOP is larger in schools where non-EAOP students have a relatively small probability of being A-G eligible.... ..."

"... In PAGE 3: ... The database consists of 235 patients with lung cancer who received three-dimensional conformal, external-beam RT at Duke University Medical Center on an Institutional Review Board approved protocol (protocol title: prospective study of the influence of external beam radiation on pulmonary function (whole organ and regional) with radiographic correlations; protocol number: IRB 1698). Table1 lists the patient and treatment characteristics.... ..."

"... In PAGE 27: ... Here, our chart- review data allow us to evaluate the extent to which a broad range of treatments differed across hospitals. Table3 reports similar GMM estimates of the true variation across hospitals for nine selected treatment measures. Again, the standard deviation in treatment rates across hospitals is large for most of the measures, e.... In PAGE 32: ... (1994) have proven feasible for analyzing several treatments, they are difficult to apply to models with many treatments, because it is difficult to identify additional strong instruments that generate significant independent variation in the additional treatments. In Table 5, we make use of the large variation across hospitals in a broad range of heart attack treatments, including but not limited to the illustrative treatments described in Table3 . In particular, we use factor models (equation 8) to estimate the mortality effects of underlying factors that summarize the impact on mortality of groups of treatments that tend to vary together.... ..."

"... In PAGE 26: ...11): the aggregate sub-regional unobserved group effects are correlated with the training status. In column (2) of Table5 we report the estimates of the constant treatment effect model. In contrast, with the variable treatment model, the point estimate of the mean selection bias is large and negative.... In PAGE 26: ...post participation. In Appendix D.1 we derive how this affects our regression specification. The estimation results can be found in column (3) of Table5... In PAGE 27: ... We derive in Appendix D.2 how this affects the specification of the variable treatment effects. Column (4) of Table5 reports the findings of this model. The point estimates are very different.... ..."

"... In PAGE 5: ... 4C). The estrogen-induced/AP-1-dependent genes were up-regulated by estrogen treatment under conditions of normal AP-1 but not up-regulated by estrogen when AP-1 was blocked ( Table2 ). This analysis yielded 21 genes whose average expression profile is shown in Fig.... In PAGE 13: ... The cumulative effect of changes in the expression of these genes is blockade of estrogen-induced breast cancer cell growth (16). Our results also show that TAM67 can block estro- gen-induction of several genes involved in cell motility and invasion, including FN1, EMS1, tropomyosin 1, and actinin H92511 (see Table2 ). Thus, agents that block AP-1 can suppress both cell growth and invasion.... ..."

"... In PAGE 3: ... These differences might arise from the different numbers of data collected from the two microarrays. Table1 lists the highly induced genes according to their average induction values obtained from the ORF and Oligo DNA microarrays without any statistical selection. The most highly induced gene was FRM2 followed by AADs, FLR1, OYE3, GRE2, and MET17.... In PAGE 4: ... Although our results suggest that cit- rinin affected mitochondria, but we can not say that the citrinin toxicity is specific to mitochondria. In the list of highly induced genes ( Table1 ), the YLR346C, GTT2, PDR5, and YKL070W genes (shown in bold in Table 1) were counted as the gene products localized in the mito- chondria. As these genes are also expressed in other Correlation factors among the different experiments (same conditions but different treatments) Figure 3 Correlation factors among the different experiments (same conditions but different treatments).... ..."

"... In PAGE 3: ... There was a strong positive correla- tion for all of these methods. Linear-regression analysis of the data plotted in Figure 3, as seen in Table1 , demonstrates that the Pearson correlation coefficient of the computer count with the manual count standard most nearly ap- proached unity, with a value of 0.9911.... ..."